Development and evaluation of a decision Aid for BRCA carriers with breast cancer

Journal of Genetic Counseling

Volumn 20, Issue 3, 2011, Pages 294-307

  Culver, Julie O ^a   MacDonald, Deborah J ^a   Thornton, Andrea A ^a   Sand, Sharon R ^a   Grant, Marcia ^a   Bowen, Deborah J ^b   Burke, Harry ^c   Garcia, Nellie ^a   Metcalfe, Kelly A ^d   Weitzel, Jeffrey N ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

BRCA1; BRCA2; Breast cancer; Decision aid; Decision making; Genetic counseling; Mastectomy; Oophorectomy

Indexed keywords

ARTICLE; BREAST TUMOR; DECISION SUPPORT SYSTEM; FEMALE; GENETIC COUNSELING; GENETICS; HETEROZYGOTE DETECTION; HUMAN; INFORMATION PROCESSING; MASTECTOMY; OVARIECTOMY; PSYCHOLOGICAL ASPECT; RISK REDUCTION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; DECISION SUPPORT TECHNIQUES; FEMALE; FOCUS GROUPS; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; HETEROZYGOTE DETECTION; HUMANS; MASTECTOMY; OVARIECTOMY; RISK REDUCTION BEHAVIOR;

EID: 79958772733     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-011-9350-4     Document Type: Article

References (60)

1. Ancker, J. S., Senathirajah, Y., Kukafka, R., & Starren, J. B. (2006). Design features of graphs in health risk communication: a systematic review. Journal of the American Medical Informatics Association, 13(6), 608-618. (Pubitemid 44649360)
2. Antoniou, A., Pharoah, P. D., Narod, S., Risch, H. A., Eyfjord, J. E., Hopper, J. L., et al. (2003). Average risks of breast and ovarian cancer associated with Brca1 or Brca2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. American Journal of Human Genetics, 72(5), 1117-1130. doi:10.1086/375033. (Pubitemid 36530000)
3. Atomic Design, L. (2006). Selectsurvey.Net 2.3.4. ClassApps.com Retrieved March 2007 www.selectsurvey.net
4. Barton, M. B., West, C. N., Liu, I. L., Harris, E. L., Rolnick, S. J., Elmore, J. G., et al. (2005). Complications following bilateral prophylactic mastectomy. Journal of the National Cancer Institute Monographs, 35, 61-66.
5. Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology, 3(2), 77-101.
6. Brown, S. M., Culver, J. O., Osann, K. E., MacDonald, D. J., Sand, S., Thornton, A. A., et al. (2010). Health literacy, numeracy, and interpretation of graphical breast cancer risk estimates. Patient Education and Counseling, Epub ahead of print, June 4 2010.
7. Burke, H., Hoang, A., Metcalfe, K., Culver, J., MacDonald, D., Grant, M., et al. (2007). Individualized risk predictions to estimate the clinical benefit of risk reduction mastectomy (Rrm) and oophorectomy (Rrso) in Brca carriers with breast cancer. 57th Annual American Society of Human Genetics Meeting (Vol. 72, pp. 103). San Diego, CA. Retrieved from http://www.ashg.org/genetics/ashg/ annmeet/2007/
8. Claes, E., Evers-Kiebooms, G., Decruyenaere, M., Denayer, L., Boogaerts, A., Philippe, K., et al. (2005). Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behavioral Medicine, 31(3), 93-105. (Pubitemid 41476567)
9. Crotser, C. B., & Boehmke, M. (2009). Survivorship considerations in adults with hereditary breast and ovarian cancer syndrome: state of the science. Journal of Cancer Survivorship, 3(1), 21-42.
10. Croyle, R. T., Smith, K. R., Botkin, J. R., Baty, B., & Nash, J. (1997). Psychological responses to Brca1 mutation testing: preliminary findings. Health Psychology, 16(1), 63-72. (Pubitemid 127465954)
11. Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., et al. (2010). Association of risk-reducing surgery in Brca1 or Brca2 mutation carriers with cancer risk and mortality. JAMA, 304(9), 967-975. doi:10.1001/jama.2010.1237.
12. Eisen, A., Lubinski, J., Klijn, J., Moller, P., Lynch, H. T., Offit, K., et al. (2005). Breast cancer risk following bilateral oophorectomy in Brca1 and Brca2 mutation carriers: an international case-control study. Journal of Clinical Oncology, 23(30), 7491-7496. (Pubitemid 46291812)
13. Elit, L., Esplen, M. J., Butler, K., & Narod, S. (2001). Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Familial Cancer, 1(3-4), 149-156.
14. Elwyn, G., O'Connor, A., Stacey, D., Volk, R., Edwards, A., Coulter, A., et al. (2006). Developing a quality criteria framework for patient decision aids: Online International Delphi Consensus Process. BMJ, 333(7565), 417.
15. Ferrell, B. R., Grant, M. M., Funk, B., Otis-Green, S., & Garcia, N. (1997). Quality of life in breast cancer survivors as identified by focus groups. Psycho-Oncology, 6, 13-25.
16. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., et al. (1998). Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. Journal of the National Cancer Institute, 90(18), 1371-1388. (Pubitemid 28439961)
17. Ford, D., Easton, D. F., Bishop, D. T., Narod, S. A., Goldgar, D. E., & Consortium, T. B. C. L. (1994). Risks of cancer in Brca1-mutation carriers. Lancet, 343, 692-695. (Pubitemid 24087847)
18. Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., et al. (1998). Genetic heterogeneity and penetrance analysis of the Brca1 and Brca2 genes in breast cancer families. American Journal of Human Genetics, 62, 676-689. doi:10.1086/301749. (Pubitemid 28164626)
19. Fortin, J. M., Hirota, L. K., Bond, B. E., O'Connor, A. M., & Col, N. F. (2001). Identifying patient preferences for communicating risk estimates: a descriptive pilot study. BMC Medical Informatics and Decision Making, 1(1), 2.
20. Gronwald, J., Tung, N., Foulkes, W. D., Offit, K., Gershoni, R., Daly, M., et al. (2006). Tamoxifen and contralateral breast cancer in Brca1 and Brca2 carriers: an update. International Journal of Cancer, 118(9), 2281-2284.
21. Hallowell, N., Jacobs, I., Richards, M., Mackay, J., & Gore, M. (2001). Surveillance or surgery? A description of the factors that influence high risk premenopausal women's decisions about prophylactic oophorectomy. Journal of Medical Genetics, 38(10), 683-691. (Pubitemid 32946790)
22. Hartmann, L. C., Schaid, D. J., Woods, J. E., Crotty, T. P., Myers, J. L., Arnold, P. G., et al. (1999). Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. The New England Journal of Medicine, 340(2), 77-84. (Pubitemid 29054841)
23. Hooker, G. W., Leventhal, K. G., Demarco, T., Peshkin, B. N., Finch, C., Wahl, E., et al. (2010). Longitudinal changes in patient distress following interactive decision aid use among Brca1/2 carriers: a randomized trial. Medical Decision Making. doi:10.1177/0272989X10381283.
24. Hsieh, H. F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. Qualitative Health Research, 15(9), 1277-1288.
25. Kauff, N. D., Satagopan, J. M., Robson, M. E., Scheuer, L., Hensley, M., Hudis, C. A., et al. (2002). Risk-reducing Salpingooophorectomy in women with a Brca1 or Brca2 mutation. The New England Journal of Medicine, 346(21), 1609-1615. (Pubitemid 34755668)
26. King, M.-C., Wieand, S., Hale, K., Lee, M., Walsh, T., Owens, K., et al. (2001). Tamoxifen and breast cancer incidence among women with inherited mutations in Brca1 and Brca2: national surgical adjuvant breast and bowel project (Nsabp-P1) breast cancer prevention trial. JAMA, 286(18), 2251-2256. (Pubitemid 33063147)
27. Kramer, J. L., Velazquez, I. A., Chen, B. E., Rosenberg, P. S., Struewing, J. P., & Greene, M. H. (2005). Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of Brca1 mutation carriers. Journal of Clinical Oncology, 23(34), 8629-8635. (Pubitemid 46211505)
28. Krueger, R. A., & Casey, M. A. (2000). Focus groups: A practical guide for applied research (vol. edition). Thousand Oaks, Calif.
29. Lloyd, S. M., Watson, M., Oaker, G., Sacks, N., Querci della Rovere, U., & Gui, G. (2000). Understanding the experience of prophylactic mastectomy: a qualitative study of ten women. Psycho-Oncology, 9(6), 473-485. (Pubitemid 32010920)
30. MacDonald, D. J., Choi, J., Ferrell, B., Sand, S., McCaffrey, S., Blazer, K. R., et al. (2002). Concerns of women presenting to a comprehensive cancer center for genetic cancer risk assessment. Journal of Medical Genetics, 39(7), 526-530. (Pubitemid 34787750)
31. Mai, P. L., Lagos, V. I., Palomares, M. R., & Weitzel, J. N. (2008). Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment. Annals of Surgical Oncology, 15(12), 3415-3421. doi:10.1245/s10434-008-0160-3.
32. McDonnell, S. K., Schaid, D. J., Myers, J. L., Grant, C. S., Donohue, J. H., Woods, J. E., et al. (2001). Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. Journal of Clinical Oncology, 19, 3938-3943. (Pubitemid 32912020)
33. Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., et al. (2004). Contralateral breast cancer in Brca1 and Brca2 mutation carriers. Journal of Clinical Oncology, 22(12), 2328-2335. doi:10.1200/JCO.2004.04.033. (Pubitemid 41115389)
34. Metcalfe, K. A., Poll, A., O'Connor, A., Gershman, S., Armel, S., Finch, A., et al. (2007). Development and testing of a decision aid for breast cancer prevention for women with a Brca1 or Brca2 mutation. Clinical Genetics, 72(3), 208-217. (Pubitemid 47300023)
35. Modugno, F. (2003). Ovarian cancer and high-risk women-implications for prevention, screening, and early detection. Gynecologic Oncology, 91(1), 15-31.
36. Muhr, T. (2005). Atlas.Ti (Version 5.0). Berlin. Retrieved from www.atlasti.com
37. Narod, S. A., Brunet, J. S., Ghadirian, P., Robson, M., Heimdal, K., Neuhausen, S. L., et al. (2000). Tamoxifen and risk of contralateral breast cancer in Brca1 and Brca2 mutation carriers: a case-control study. Lancet, 356, 1876-1881. doi:10.1016/S0140-6736(00)03258-X.
38. NCCN (2010). NCCN Practice Guidelines V.1.2010: Genetic/Familial High-Risk Assessment: Breast and Ovarian. NCCN Practice Guidelines, 8(5), 562-594. Retrieved from http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd= Retrieve&db=PubMed&dopt=Citation&list-uids=20495085
39. Neuendorf, K. (2002). The content analysis guidebook. Thousand Oaks: Sage.
40. O'Brien, M. A., Whelan, T. J., Villasis-Keever, M., Gafni, A., Charles, C., Roberts, R., et al. (2009). Are cancer-related decision aids effective? A systematic review and meta-analysis. Journal of Clinical Oncology, 27(6), 974-985. doi:10.1200/jco.2007.16.0101.
41. O'Connor, A. M., Stacey, D., Entwistle, V., Llewellyn-Thomas, H., Rovner, D., Holmes-Rovner, M., et al. (2004). Decision aids for people facing health treatment or screening decisions. Cochrane Database of Systematic Reviews Issue 1. Retrieved 11 May 2005, from http://204.187.39.28/cochsystem.html
42. O'Connor, A. M. (1995). Validation of a decisional conflict scale. Medical Decision Making, 15(1), 25-30.
43. O'Connor, A. M., Tugwell, P., Wells, G. A., Elmslie, T., Jolly, E., Hollingworth, G., et al. (1998). Randomized trial of a portable, self-administered decision aid for postmenopausal women considering long-term preventive hormone therapy. Medical Decision Making, 18(3), 295-303. (Pubitemid 28307560)
44. O'Connor, A. M., Fiset, V., DeGrasse, C., Graham, I. D., Evans, W., Stacey, D., et al. (1999). Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. Journal of the National Cancer Institute Monographs, 25, 67-80.
45. Rebbeck, T. R., Levin, A. M., Eisen, A., Snyder, C., Watson, P., Cannon-Albright, L., et al. (1999). Breast cancer risk after bilateral prophylactic oophorectomy in Brca1 mutation carriers. Journal of the National Cancer Institute, 91, 1475-1479. (Pubitemid 29424552)
46. Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., Van't Veer, L., Garber, J. E., et al. (2002). Prophylactic oophorectomy in carriers of Brca1 or Brca2 mutations. The New England Journal of Medicine, 346(21), 1616-1622.
47. Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van't Veer, L., Garber, J. E., et al. (2004). Bilateral prophylactic mastectomy reduces breast cancer risk in Brca1 and Brca2 mutation carriers: the prose study group. Journal of Clinical Oncology, 22(6), 1055-1062. doi:10.1200/jco.2004.04.188.
48. Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in Brca1 or Brca2 mutation carriers. Journal of the National Cancer Institute, 101(2), 80-87. doi:10.1093/jnci/djn442.
49. Schwartz, M. D., Lerman, C., Brogan, B., Peshkin, B. N., Hughes Halbert, C., DeMarco, T., et al. (2004). Impact of Brca1/Brca2 counseling and testing on newly diagnosed breast cancer patients. Journal of Clinical Oncology, 22(10), 1823-1829. (Pubitemid 41095172)
50. Schwartz, M. D., Peshkin, B. N., Tercyak, K. P., Taylor, K. L., & Valdimarsdottir, H. (2005). Decision making and decision support for hereditary breast-ovarian cancer susceptibility. [Special Issue]. Health Psychology, 24(4 Suppl), S78-S84. doi:1930-7810.
51. Schwartz, M. D., Valdimarsdottir, H. B., DeMarco, T. A., Peshkin, B. N., Lawrence, W., Rispoli, J., et al. (2009). Randomized trial of a decision aid for Brca1/Brca2 mutation carriers: impact on measures of decision making and satisfaction. Health Psychology, 28(1), 11-19. doi:10.1037/a0013147.
52. Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., et al. (1997). The risk of cancer associated with specific mutations of Brca1 and Brca2 among Ashkenazi Jews. The New England Journal of Medicine, 336(20), 1401-1408. doi:10.1056/NEJM199705153362001. (Pubitemid 27208598)
53. Tiller, K., Meiser, B., Gaff, C., Kirk, J., Dudding, T., Phillips, K. A., et al. (2006). A randomized controlled trial of a decision aid for women at increased risk of ovarian cancer. Medical Decision Making, 26(4), 360-372. (Pubitemid 44050841)
54. van Dijk, S., van Roosmalen, M. S., Otten, W., & Stalmeier, P. F. M. (2008). Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret. Journal of Clinical Oncology, 26(14), 2358-2363. doi:10.1200/jco.2006.10.5494.
55. van Roosmalen, M. S., Stalmeier, P. F., Verhoef, L. C., Hoekstra- Weebers, J. E., Oosterwijk, J. C., Hoogerbrugge, N., et al. (2004a). Randomised trial of a decision aid and its timing for women being tested for a Brca1/2 mutation. British Journal of Cancer, 90(2), 333-342. (Pubitemid 38250625)
56. van Roosmalen, M. S., Stalmeier, P. F., Verhoef, L. C., Hoekstra-Weebers, J. E., Oosterwijk, J. C., Hoogerbrugge, N., et al. (2004b). Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for Brca1/2 mutation carriers. Journal of Clinical Oncology, 22(16), 3293-3301. (Pubitemid 41103685)
57. Waljee, J. F., Rogers, M. A., & Alderman, A. K. (2007). Decision aids and breast cancer: do they influence choice for surgery and knowledge of treatment options? Journal of Clinical Oncology, 25(9), 1067-1073.
58. Watson, M., Foster, C., Eeles, R., Eccles, D., Ashley, S., Davidson, R., et al. (2004). Psychosocial impact of breast/ovarian (Brca1/2) cancer-predictive genetic testing in a UK Multi-Centre Clinical Cohort. British Journal of Cancer, 91(10), 1787-1794. (Pubitemid 39664966)
59. Weitzel, J. N., McCaffrey, S. M., Nedelcu, R., MacDonald, D. J., Blazer, K. R., & Cullinane, C. A. (2003). Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Archives of Surgery, 138(12), 1323-1329. (Pubitemid 37499389)
60. Whelan, T., Levine, M., Willan, A., Gafni, A., Sanders, K., Mirsky, D., et al. (2004). Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. JAMA, 292(4), 435-441. (Pubitemid 38988952)